| 1 |
34222724 | Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis. | 2021 Jun |
1 |
| 2 |
27180612 | Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. | 2017 Jan |
1 |
| 3 |
27560285 | Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents. | 2016 Nov 29 |
3 |
| 4 |
29879349 | [Synthesis and biological activity of substituted xanthines as DPP-Ⅳ inhibitors]. | 2016 Jun |
1 |
| 5 |
24481594 | Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4. | 2014 Feb |
2 |
| 6 |
25065332 | Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. | 2014 Sep 20 |
1 |
| 7 |
25756669 | More effective DPP4 inhibitors as antidiabetics based on sitagliptin applied QSAR and clinical methods. | 2014 |
3 |
| 8 |
23305140 | 3D QSAR and docking study of gliptin derivatives as DPP-IV inhibitors. | 2013 May |
1 |
| 9 |
23358258 | Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4. | 2013 |
4 |
| 10 |
23748509 | Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin. | 2013 May |
1 |
| 11 |
24900744 | Integrated Synthesis and Testing of Substituted Xanthine Based DPP4 Inhibitors: Application to Drug Discovery. | 2013 Aug 8 |
1 |
| 12 |
22420306 | Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor. | 2012 Jun |
1 |
| 13 |
21916836 | Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus. | 2011 Sep |
1 |
| 14 |
19947894 | Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. | 2010 Jan |
3 |
| 15 |
19426127 | Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes. | 2009 Jun |
1 |
| 16 |
18485703 | 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors. | 2008 Jun 1 |
1 |
| 17 |
17352678 | Aromatic heterocycle-based DPP-IV inhibitors: xanthines and related structural types. | 2007 |
2 |
| 18 |
18052023 | 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. | 2007 Dec 27 |
1 |